By staff writers

January 11, 2018 -- GE Healthcare has received marketing clearance from Health Canada for its DaTscan (ioflupane I-123 injection) imaging agent.

DaTscan is used with SPECT to image the striatum of the brain in patients with suspected Parkinsonian syndrome, which includes Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

While DaTscan is not designed to differentiate between the three aforementioned conditions, clinicians can use the radiopharmaceutical with SPECT to help distinguish between Parkinsonian syndrome and essential tremor.

GE said it plans to make DaTscan commercially available in Canada early this year.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking